[Form 4] Castle Biosciences, Inc. Insider Trading Activity
Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences, Inc. (CSTL), reported the sale of 18,007 shares of the issuer's common stock on 08/27/2025. The sales were executed in multiple trades at prices ranging from $21.24 to $21.94, with a reported weighted-average sale price of $21.69. Following the reported disposition, Oelschlager beneficially owned 153,793 shares, held directly. The Form 4 was signed by an attorney-in-fact, Frank Stokes, on 08/29/2025. The filer affirms availability to provide trade-level price and share details upon request.
Kristen M. Oelschlager, Chief Operating Officer di Castle Biosciences, Inc. (CSTL), ha venduto 18.007 azioni ordinarie della societ脿 il 27/08/2025. Le vendite sono state effettuate in pi霉 operazioni a prezzi compresi tra $21,24 e $21,94, con un prezzo medio ponderato riportato di $21,69. Dopo la cessione indicata, Oelschlager deteneva beneficiariamente 153.793 azioni, possedute direttamente. Il Modulo 4 猫 stato firmato per procura dall'avvocato Frank Stokes in data 29/08/2025. Il dichiarante conferma la disponibilit脿 a fornire, su richiesta, i dettagli a livello di singola operazione relativi a prezzo e numero di azioni.
Kristen M. Oelschlager, directora de operaciones (COO) de Castle Biosciences, Inc. (CSTL), inform贸 la venta de 18.007 acciones ordinarias de la emisora el 27/08/2025. Las ventas se realizaron en m煤ltiples operaciones a precios que oscilaron entre $21.24 y $21.94, con un precio medio ponderado informado de $21.69. Tras la disposici贸n reportada, Oelschlager pose铆a beneficiariamente 153.793 acciones, mantenidas de forma directa. El Formulario 4 fue firmado por poder por el apoderado Frank Stokes el 29/08/2025. El declarante afirma estar disponible para proporcionar, a solicitud, los detalles por operaci贸n sobre precios y cantidades.
Kristen M. Oelschlager雼橃潃 Castle Biosciences, Inc.(CSTL)鞚� 斓滉碃鞖挫榿毂呾瀯鞛�(COO)搿滌劀 2025-08-27鞐� 氚滍枆須岇偓鞚� 氤错喌欤� 18,007欤茧ゼ 毵る弰頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 毵る弰電� 鞐煬 彀鞚� 瓯半灅搿� 鞚措（鞏挫鞙茧┌ 瓯半灅 臧�瓴╈潃 $21.24~$21.94 氩旍渼鞓�瓿�, 鞁犼碃霅� 臧�欷� 韽夑窢 毵る弰 臧�瓴╈潃 $21.69鞓�鞀惦媹雼�. 鞁犼碃霅� 觳橂秳 鞚错泟 Oelschlager電� 歆侅爲 氤挫湢 順曧儨搿� 153,793欤茧ゼ 鞁れ鞝侅溂搿� 靻岇湢頃橁碃 鞛堨棃鞀惦媹雼�. Form 4電� Frank Stokes臧� 雽�毽 靹滊獏頄堨溂氅� 靹滊獏鞚检潃 2025-08-29鞛呺媹雼�. 鞝滌稖鞛愲姅 鞖旍箔 鞁� 臧滊硠 瓯半灅氤� 臧�瓴� 氚� 欤检嫕 靾� 靹鸽秬靷暛鞚� 鞝滉车頃� 靾� 鞛堨潓鞚� 頇曥澑頃╇媹雼�.
Kristen M. Oelschlager, directrice des op茅rations de Castle Biosciences, Inc. (CSTL), a d茅clar茅 la vente de 18 007 actions ordinaires de l'茅metteur le 27/08/2025. Les cessions ont 茅t茅 r茅alis茅es en plusieurs transactions 脿 des prix allant de 21,24 $ 脿 21,94 $, avec un prix moyen pond茅r茅 d茅clar茅 de 21,69 $. Suite 脿 la cession signal茅e, Oelschlager d茅tenait 脿 titre b茅n茅ficiaire 153 793 actions, d茅tenues directement. Le formulaire 4 a 茅t茅 sign茅 par procuration par Frank Stokes le 29/08/2025. Le d茅clarant confirme sa disponibilit茅 脿 fournir, sur demande, les d茅tails au niveau de chaque transaction concernant les prix et le nombre d'actions.
Kristen M. Oelschlager, Chief Operating Officer von Castle Biosciences, Inc. (CSTL), meldete den Verkauf von 18.007 Stammaktien des Emittenten am 27.08.2025. Die Verk盲ufe erfolgten in mehreren Transaktionen zu Preisen zwischen $21,24 und $21,94, mit einem gemeldeten gewichteten Durchschnittspreis von $21,69. Nach der gemeldeten Ver盲u脽erung besa脽 Oelschlager wirtschaftlich 153.793 Aktien, die direkt gehalten wurden. Das Formular 4 wurde am 29.08.2025 von einem Bevollm盲chtigten, Frank Stokes, unterzeichnet. Der Einreicher best盲tigt, auf Anfrage Transaktionsdetails zu Einzelpreisen und St眉ckzahlen zur Verf眉gung stellen zu k枚nnen.
- None.
- None.
Insights
TL;DR: Officer sold a modest block of shares; ownership remains material but no other disclosures indicate company-impacting events.
The reported sale of 18,007 shares at a weighted-average price of $21.69 reduced the reporting officer's direct stake to 153,793 shares. This is a routine Section 16 disclosure showing an executive liquidity event rather than a change in control or compensation grant. The Form 4 discloses execution across multiple trades and offers to provide granular trade details on request, which supports transparency. Absent additional company disclosures, this filing alone is informational and carries limited standalone market impact.
TL;DR: Transaction is a standard insider sale reported under Section 16; governance procedures appear followed via attorney-in-fact filing.
The filing identifies the reporting person as an officer and indicates the Form 4 was filed by a single reporting person and signed by an attorney-in-fact. The explanation notes multiple trade executions and a weighted-average price; the willingness to provide full trade-level details aligns with compliance norms. There is no indication of trading pursuant to a Rule 10b5-1 plan in the form text provided.
Kristen M. Oelschlager, Chief Operating Officer di Castle Biosciences, Inc. (CSTL), ha venduto 18.007 azioni ordinarie della societ脿 il 27/08/2025. Le vendite sono state effettuate in pi霉 operazioni a prezzi compresi tra $21,24 e $21,94, con un prezzo medio ponderato riportato di $21,69. Dopo la cessione indicata, Oelschlager deteneva beneficiariamente 153.793 azioni, possedute direttamente. Il Modulo 4 猫 stato firmato per procura dall'avvocato Frank Stokes in data 29/08/2025. Il dichiarante conferma la disponibilit脿 a fornire, su richiesta, i dettagli a livello di singola operazione relativi a prezzo e numero di azioni.
Kristen M. Oelschlager, directora de operaciones (COO) de Castle Biosciences, Inc. (CSTL), inform贸 la venta de 18.007 acciones ordinarias de la emisora el 27/08/2025. Las ventas se realizaron en m煤ltiples operaciones a precios que oscilaron entre $21.24 y $21.94, con un precio medio ponderado informado de $21.69. Tras la disposici贸n reportada, Oelschlager pose铆a beneficiariamente 153.793 acciones, mantenidas de forma directa. El Formulario 4 fue firmado por poder por el apoderado Frank Stokes el 29/08/2025. El declarante afirma estar disponible para proporcionar, a solicitud, los detalles por operaci贸n sobre precios y cantidades.
Kristen M. Oelschlager雼橃潃 Castle Biosciences, Inc.(CSTL)鞚� 斓滉碃鞖挫榿毂呾瀯鞛�(COO)搿滌劀 2025-08-27鞐� 氚滍枆須岇偓鞚� 氤错喌欤� 18,007欤茧ゼ 毵る弰頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 毵る弰電� 鞐煬 彀鞚� 瓯半灅搿� 鞚措（鞏挫鞙茧┌ 瓯半灅 臧�瓴╈潃 $21.24~$21.94 氩旍渼鞓�瓿�, 鞁犼碃霅� 臧�欷� 韽夑窢 毵る弰 臧�瓴╈潃 $21.69鞓�鞀惦媹雼�. 鞁犼碃霅� 觳橂秳 鞚错泟 Oelschlager電� 歆侅爲 氤挫湢 順曧儨搿� 153,793欤茧ゼ 鞁れ鞝侅溂搿� 靻岇湢頃橁碃 鞛堨棃鞀惦媹雼�. Form 4電� Frank Stokes臧� 雽�毽 靹滊獏頄堨溂氅� 靹滊獏鞚检潃 2025-08-29鞛呺媹雼�. 鞝滌稖鞛愲姅 鞖旍箔 鞁� 臧滊硠 瓯半灅氤� 臧�瓴� 氚� 欤检嫕 靾� 靹鸽秬靷暛鞚� 鞝滉车頃� 靾� 鞛堨潓鞚� 頇曥澑頃╇媹雼�.
Kristen M. Oelschlager, directrice des op茅rations de Castle Biosciences, Inc. (CSTL), a d茅clar茅 la vente de 18 007 actions ordinaires de l'茅metteur le 27/08/2025. Les cessions ont 茅t茅 r茅alis茅es en plusieurs transactions 脿 des prix allant de 21,24 $ 脿 21,94 $, avec un prix moyen pond茅r茅 d茅clar茅 de 21,69 $. Suite 脿 la cession signal茅e, Oelschlager d茅tenait 脿 titre b茅n茅ficiaire 153 793 actions, d茅tenues directement. Le formulaire 4 a 茅t茅 sign茅 par procuration par Frank Stokes le 29/08/2025. Le d茅clarant confirme sa disponibilit茅 脿 fournir, sur demande, les d茅tails au niveau de chaque transaction concernant les prix et le nombre d'actions.
Kristen M. Oelschlager, Chief Operating Officer von Castle Biosciences, Inc. (CSTL), meldete den Verkauf von 18.007 Stammaktien des Emittenten am 27.08.2025. Die Verk盲ufe erfolgten in mehreren Transaktionen zu Preisen zwischen $21,24 und $21,94, mit einem gemeldeten gewichteten Durchschnittspreis von $21,69. Nach der gemeldeten Ver盲u脽erung besa脽 Oelschlager wirtschaftlich 153.793 Aktien, die direkt gehalten wurden. Das Formular 4 wurde am 29.08.2025 von einem Bevollm盲chtigten, Frank Stokes, unterzeichnet. Der Einreicher best盲tigt, auf Anfrage Transaktionsdetails zu Einzelpreisen und St眉ckzahlen zur Verf眉gung stellen zu k枚nnen.
FAQ
What did Kristen M. Oelschlager report on Form 4 for CSTL?
When were the CSTL shares sold and at what prices?
Does the Form 4 indicate the sale was part of a 10b5-1 trading plan?
How many shares does Oelschlager own after the sale?
Who signed the Form 4 filing for the reporting person?
